Cargando…
The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury
BACKGROUND: The lung is one of the most sensitive organs, and is vulnerable to injury caused by limb ischemia-reperfusion (LIR). Dexmedetomidine, an anesthetic adjunct, has been shown to have therapeutic effects on lung injury secondary to LIR. This study aimed to investigate the role of dexmedetomi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011293/ https://www.ncbi.nlm.nih.gov/pubmed/35434046 http://dx.doi.org/10.21037/atm-22-711 |
_version_ | 1784687658040033280 |
---|---|
author | Wang, Lei Ding, Yanling Bai, Yanhui Shi, Jian Li, Jia Wang, Xiuli |
author_facet | Wang, Lei Ding, Yanling Bai, Yanhui Shi, Jian Li, Jia Wang, Xiuli |
author_sort | Wang, Lei |
collection | PubMed |
description | BACKGROUND: The lung is one of the most sensitive organs, and is vulnerable to injury caused by limb ischemia-reperfusion (LIR). Dexmedetomidine, an anesthetic adjunct, has been shown to have therapeutic effects on lung injury secondary to LIR. This study aimed to investigate the role of dexmedetomidine in ameliorating LIR-induced lung injury in a mouse model of bilateral hind LIR. METHODS: In this study, 75 mice were randomly divided into 5 groups to prepare the LIR model. After the model was established, arterial blood was extracted for blood gas analysis. The pathological changes of lung tissue, lung wet/dry weight ratio, arterial blood gas analysis, detection of myeloperoxidase (MPO) activity, the content of reactive oxygen species (ROS), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and malondialdehyde (MDA) in oxidative stress indexes, mitochondrial membrane potential (MMP), adenosine triphosphate (ATP) content and cytochrome c content were measured, and the relative protein expression levels of sirtuin-3 (SIRT3) and apoptosis factor Bcl-2 related X protein (Bax), B-cell Lymphoma 2 (Bcl-2), cleaved caspase 3, and nuclear factor erythroid 2-related factor 2 (Nrf2) and cytoplasmic heme oxygenase-1 (HO-1). RESULTS: Pretreatment with dexmedetomidine dramatically ameliorated LIR-induced lung injury, the wet/dry weight ratio, the arterial blood gas parameters, and enhanced SIRT3 expression. Moreover, dexmedetomidine significantly inhibits ROS and MDA level and restores antioxidant enzyme activities (SOD, GSH-Px). Of note, dexmedetomidine suppressed LIR-induced lung tissue apoptosis by modulating apoptosis-associated protein such as Bax, Bcl-2, and cleaved caspase 3. Moreover, dexmedetomidine inhibited the LIR-induced decreases in MMP, ATP levels, and the release of cytochrome c of LIR to maintain mitochondrial function. Latest study has shown that activating Nrf2 could promote SIRT3 expression to alleviate IR injury. Intriguingly, dexmedetomidine could facilitate nuclear Nrf2 and cytoplasmic HO-1 expression. CONCLUSIONS: Our findings suggest that dexmedetomidine protects against LIR-induced lung injury by inhibiting the oxidative response, mitochondrial dysfunction and apoptosis. The mechanism appears to be at least partly mediated through the upregulation of SIRT3 expression. |
format | Online Article Text |
id | pubmed-9011293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-90112932022-04-16 The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury Wang, Lei Ding, Yanling Bai, Yanhui Shi, Jian Li, Jia Wang, Xiuli Ann Transl Med Original Article BACKGROUND: The lung is one of the most sensitive organs, and is vulnerable to injury caused by limb ischemia-reperfusion (LIR). Dexmedetomidine, an anesthetic adjunct, has been shown to have therapeutic effects on lung injury secondary to LIR. This study aimed to investigate the role of dexmedetomidine in ameliorating LIR-induced lung injury in a mouse model of bilateral hind LIR. METHODS: In this study, 75 mice were randomly divided into 5 groups to prepare the LIR model. After the model was established, arterial blood was extracted for blood gas analysis. The pathological changes of lung tissue, lung wet/dry weight ratio, arterial blood gas analysis, detection of myeloperoxidase (MPO) activity, the content of reactive oxygen species (ROS), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and malondialdehyde (MDA) in oxidative stress indexes, mitochondrial membrane potential (MMP), adenosine triphosphate (ATP) content and cytochrome c content were measured, and the relative protein expression levels of sirtuin-3 (SIRT3) and apoptosis factor Bcl-2 related X protein (Bax), B-cell Lymphoma 2 (Bcl-2), cleaved caspase 3, and nuclear factor erythroid 2-related factor 2 (Nrf2) and cytoplasmic heme oxygenase-1 (HO-1). RESULTS: Pretreatment with dexmedetomidine dramatically ameliorated LIR-induced lung injury, the wet/dry weight ratio, the arterial blood gas parameters, and enhanced SIRT3 expression. Moreover, dexmedetomidine significantly inhibits ROS and MDA level and restores antioxidant enzyme activities (SOD, GSH-Px). Of note, dexmedetomidine suppressed LIR-induced lung tissue apoptosis by modulating apoptosis-associated protein such as Bax, Bcl-2, and cleaved caspase 3. Moreover, dexmedetomidine inhibited the LIR-induced decreases in MMP, ATP levels, and the release of cytochrome c of LIR to maintain mitochondrial function. Latest study has shown that activating Nrf2 could promote SIRT3 expression to alleviate IR injury. Intriguingly, dexmedetomidine could facilitate nuclear Nrf2 and cytoplasmic HO-1 expression. CONCLUSIONS: Our findings suggest that dexmedetomidine protects against LIR-induced lung injury by inhibiting the oxidative response, mitochondrial dysfunction and apoptosis. The mechanism appears to be at least partly mediated through the upregulation of SIRT3 expression. AME Publishing Company 2022-03 /pmc/articles/PMC9011293/ /pubmed/35434046 http://dx.doi.org/10.21037/atm-22-711 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Wang, Lei Ding, Yanling Bai, Yanhui Shi, Jian Li, Jia Wang, Xiuli The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury |
title | The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury |
title_full | The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury |
title_fullStr | The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury |
title_full_unstemmed | The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury |
title_short | The activation of SIRT3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury |
title_sort | activation of sirt3 by dexmedetomidine mitigates limb ischemia-reperfusion–induced lung injury |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011293/ https://www.ncbi.nlm.nih.gov/pubmed/35434046 http://dx.doi.org/10.21037/atm-22-711 |
work_keys_str_mv | AT wanglei theactivationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT dingyanling theactivationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT baiyanhui theactivationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT shijian theactivationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT lijia theactivationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT wangxiuli theactivationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT wanglei activationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT dingyanling activationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT baiyanhui activationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT shijian activationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT lijia activationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury AT wangxiuli activationofsirt3bydexmedetomidinemitigateslimbischemiareperfusioninducedlunginjury |